MedTrace Logo

A Study of Lasmiditan on the Heart in Healthy Participants

NCT03465436 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2020-01-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream and how long it took the body to get rid of it. Information about side effects was collected. The study lasted a maximum of 46 days for each participant, not including screening.

Conditions

  • Healthy

Interventions

DRUG

Lasmiditan

100 mg administered orally (PO)

DRUG

Lasmiditan

400 mg administered PO

DRUG

Placebo

Placebo administered for lasmiditan or moxifloxacin

DRUG

Moxifloxacin

400 mg moxifloxacin administered PO

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-16
Primary Completion
2011-12-20
Completion
2011-12-20
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03465436 on ClinicalTrials.gov